Anticholinergic medications: An additional contributor to cognitive impairment in the heart failure population?

Arslan Shaukat, Amir Habib, Kathleen A. Lane, Changyu Shen, Saba Khan, Yaron M. Hellman, Malaz Boustani, Adnan S. Malik

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Objectives: Patients with congestive heart failure (CHF) have a high prevalence of cognitive impairment and the association is multifactorial. In general, the burden of anticholinergic drugs has consistently been shown to be a risk factor for cognitive impairment in the elderly. The aim of this study was to assess the cognitive burden of medications in patients with CHF. Design: This was a cross-sectional, retrospective, single-center study. Setting: The study was conducted in an outpatient setting. Participants: Patients who presented to a comprehensive heart failure clinic during a 1-month period were included. Measurements: The primary outcomes of interest were mean anticholinergic cognitive burden (ACB) score of all medications and CHF medications (ACB-CHF), calculated based on the ACB Scoring Scale (ACB-SS). The ACB-CHF score was further dichotomized as 0 or 1 (low anticholinergic burden) versus 2 or 3 (high anticholinergic burden). Results: A total of 182 patients were included. The mean ACB and ACB-CHF scores were 2.4 (range 0-13) and 1.0 (range 0-4), respectively, while 25.8 % of patients had an ACB-CHF score of 2 or 3. There was no association found between ejection fraction in patients with systolic heart failure and the ACB (p = 0.28) or ACB-CHF (p = 0.62) score. Conclusion: We conclude that patients with CHF have a substantial exposure to anticholinergic medications with adverse cognitive effects. This may be another important contributor to the increased prevalence of cognitive impairment in these patients.

Original languageEnglish
Pages (from-to)749-753
Number of pages5
JournalDrugs and Aging
Volume31
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Cholinergic Antagonists
Heart Failure
Population
Cognitive Dysfunction
Systolic Heart Failure
Outpatients

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Shaukat, A., Habib, A., Lane, K. A., Shen, C., Khan, S., Hellman, Y. M., ... Malik, A. S. (2014). Anticholinergic medications: An additional contributor to cognitive impairment in the heart failure population? Drugs and Aging, 31(10), 749-753. https://doi.org/10.1007/s40266-014-0204-2

Anticholinergic medications : An additional contributor to cognitive impairment in the heart failure population? / Shaukat, Arslan; Habib, Amir; Lane, Kathleen A.; Shen, Changyu; Khan, Saba; Hellman, Yaron M.; Boustani, Malaz; Malik, Adnan S.

In: Drugs and Aging, Vol. 31, No. 10, 01.10.2014, p. 749-753.

Research output: Contribution to journalArticle

Shaukat, Arslan ; Habib, Amir ; Lane, Kathleen A. ; Shen, Changyu ; Khan, Saba ; Hellman, Yaron M. ; Boustani, Malaz ; Malik, Adnan S. / Anticholinergic medications : An additional contributor to cognitive impairment in the heart failure population?. In: Drugs and Aging. 2014 ; Vol. 31, No. 10. pp. 749-753.
@article{bb753b2c38804cf3b59ae612d7cb53cd,
title = "Anticholinergic medications: An additional contributor to cognitive impairment in the heart failure population?",
abstract = "Background/Objectives: Patients with congestive heart failure (CHF) have a high prevalence of cognitive impairment and the association is multifactorial. In general, the burden of anticholinergic drugs has consistently been shown to be a risk factor for cognitive impairment in the elderly. The aim of this study was to assess the cognitive burden of medications in patients with CHF. Design: This was a cross-sectional, retrospective, single-center study. Setting: The study was conducted in an outpatient setting. Participants: Patients who presented to a comprehensive heart failure clinic during a 1-month period were included. Measurements: The primary outcomes of interest were mean anticholinergic cognitive burden (ACB) score of all medications and CHF medications (ACB-CHF), calculated based on the ACB Scoring Scale (ACB-SS). The ACB-CHF score was further dichotomized as 0 or 1 (low anticholinergic burden) versus 2 or 3 (high anticholinergic burden). Results: A total of 182 patients were included. The mean ACB and ACB-CHF scores were 2.4 (range 0-13) and 1.0 (range 0-4), respectively, while 25.8 {\%} of patients had an ACB-CHF score of 2 or 3. There was no association found between ejection fraction in patients with systolic heart failure and the ACB (p = 0.28) or ACB-CHF (p = 0.62) score. Conclusion: We conclude that patients with CHF have a substantial exposure to anticholinergic medications with adverse cognitive effects. This may be another important contributor to the increased prevalence of cognitive impairment in these patients.",
author = "Arslan Shaukat and Amir Habib and Lane, {Kathleen A.} and Changyu Shen and Saba Khan and Hellman, {Yaron M.} and Malaz Boustani and Malik, {Adnan S.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1007/s40266-014-0204-2",
language = "English",
volume = "31",
pages = "749--753",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - Anticholinergic medications

T2 - An additional contributor to cognitive impairment in the heart failure population?

AU - Shaukat, Arslan

AU - Habib, Amir

AU - Lane, Kathleen A.

AU - Shen, Changyu

AU - Khan, Saba

AU - Hellman, Yaron M.

AU - Boustani, Malaz

AU - Malik, Adnan S.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Background/Objectives: Patients with congestive heart failure (CHF) have a high prevalence of cognitive impairment and the association is multifactorial. In general, the burden of anticholinergic drugs has consistently been shown to be a risk factor for cognitive impairment in the elderly. The aim of this study was to assess the cognitive burden of medications in patients with CHF. Design: This was a cross-sectional, retrospective, single-center study. Setting: The study was conducted in an outpatient setting. Participants: Patients who presented to a comprehensive heart failure clinic during a 1-month period were included. Measurements: The primary outcomes of interest were mean anticholinergic cognitive burden (ACB) score of all medications and CHF medications (ACB-CHF), calculated based on the ACB Scoring Scale (ACB-SS). The ACB-CHF score was further dichotomized as 0 or 1 (low anticholinergic burden) versus 2 or 3 (high anticholinergic burden). Results: A total of 182 patients were included. The mean ACB and ACB-CHF scores were 2.4 (range 0-13) and 1.0 (range 0-4), respectively, while 25.8 % of patients had an ACB-CHF score of 2 or 3. There was no association found between ejection fraction in patients with systolic heart failure and the ACB (p = 0.28) or ACB-CHF (p = 0.62) score. Conclusion: We conclude that patients with CHF have a substantial exposure to anticholinergic medications with adverse cognitive effects. This may be another important contributor to the increased prevalence of cognitive impairment in these patients.

AB - Background/Objectives: Patients with congestive heart failure (CHF) have a high prevalence of cognitive impairment and the association is multifactorial. In general, the burden of anticholinergic drugs has consistently been shown to be a risk factor for cognitive impairment in the elderly. The aim of this study was to assess the cognitive burden of medications in patients with CHF. Design: This was a cross-sectional, retrospective, single-center study. Setting: The study was conducted in an outpatient setting. Participants: Patients who presented to a comprehensive heart failure clinic during a 1-month period were included. Measurements: The primary outcomes of interest were mean anticholinergic cognitive burden (ACB) score of all medications and CHF medications (ACB-CHF), calculated based on the ACB Scoring Scale (ACB-SS). The ACB-CHF score was further dichotomized as 0 or 1 (low anticholinergic burden) versus 2 or 3 (high anticholinergic burden). Results: A total of 182 patients were included. The mean ACB and ACB-CHF scores were 2.4 (range 0-13) and 1.0 (range 0-4), respectively, while 25.8 % of patients had an ACB-CHF score of 2 or 3. There was no association found between ejection fraction in patients with systolic heart failure and the ACB (p = 0.28) or ACB-CHF (p = 0.62) score. Conclusion: We conclude that patients with CHF have a substantial exposure to anticholinergic medications with adverse cognitive effects. This may be another important contributor to the increased prevalence of cognitive impairment in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84907799096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907799096&partnerID=8YFLogxK

U2 - 10.1007/s40266-014-0204-2

DO - 10.1007/s40266-014-0204-2

M3 - Article

C2 - 25142050

AN - SCOPUS:84907799096

VL - 31

SP - 749

EP - 753

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 10

ER -